Merus Nv Share Price (NASDAQ: MRUS)

$66.12

▲

-1.16

(-1.72%)

Last updated on August 29, 2025 at 1:29 am IST

$₹

Check the interactive Merus Nv Stock chart to analyse performance

Merus Nv stock performance

as on August 29, 2025 at 1:29 am IST

Today's Low:$66.11
Today's High:$69.08
$66.12
0.02%
Downside
Day's Volatility :4.3%
Upside
4.28%
52 Weeks Low:$33.19
52 Weeks High:$69.08
$66.12
49.8%
Downside
52 Weeks Volatility :51.95%
Upside
4.28%

Merus Nv Stock Returns

Period	Merus Nv	Sector (Health Care)	Index (Russel 2000)
3 Months	17.94%	3.1%	0.0%
6 Months	40.43%	-8.4%	0.0%
1 Year	31.0%	-12.6%	0.0%
3 Years	192.09%	7.9%	-6.1%

Merus Nv Key Stats

Check Merus Nv key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$67.28
Open	$67.365
Today's High	$69.08
Today's Low	$66.11
Market Capitalization	$5.1B
Today's Volume	$1.1M
52 Week High	$69.08
52 Week Low	$33.19
Revenue TTM	$56.2M
EBITDA	$-344.5M
Earnings Per Share (EPS)	$-5.58
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-48.54%

Stock Returns calculator for Merus Nv Stock including INR - Dollar returns

The Merus Nv stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Merus Nv investment value today

Current value as on today

₹1,35,539

Returns

₹35,539

(+35.54%)

Returns from Merus Nv Stock

₹30,983 (+30.98%)

Dollar Returns*

₹4,556 (+4.56%)

Indian investors sentiment towards Merus Nv Stock

-4%

Period: Jul 29, 2025 to Aug 28, 2025. Change in 30 Days versus previous period

Search interest for Merus Nv Stock from India on INDmoney has decreased by -4% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Merus Nv

Name
Holdings %
Name
Holdings %
FMR Inc
9.21%
Paradigm Biocapital Advisors LP
5.66%
RTW INVESTMENTS, LLC
5.29%
Wellington Management Company LLP
4.93%
COMMODORE CAPITAL LP
4.66%
Deerfield Management Co
4.47%

Analyst Recommendation on Merus Nv Stock

Rating

Trend

Buy

95%Buy

5%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Merus Nv(by analysts ranked 0 to 5 stars)

Merus Nv Share Price Target

What analysts predicted

Upside of 36.68%

Target:

$90.38

Current:

$66.12

Merus Nv share price target is $90.38, a slight Upside of 36.68% compared to current price of $66.12 as per analysts' prediction.

Merus Nv Stock Insights

Price Movement
In the last 3 years, MRUS stock has moved up by 184.9%
Decreasing Revenue
Revenue is down for the last 2 quarters, 26.48M → 8.82M (in $), with an average decrease of 66.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -30.92M → -158.21M (in $), with an average decrease of 138.0% per quarter
MRUS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 57.5% return, outperforming this stock by 26.5%
Price to Sales
ForMRUS every $1 of sales, investors are willing to pay $81.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.8 for every $1 of sales.

Merus Nv Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$31.1M	↓ 13.46%
Net Income	$-55.2M	↑ 98.66%
Net Profit Margin	-177.15%	↓ 99.98%

	FY20	Y/Y Change
Revenue	$29.9M	↓ 3.82%
Net Income	$-85.5M	↑ 55.05%
Net Profit Margin	-285.59%	↓ 108.44%

	FY21	Y/Y Change
Revenue	$49.1M	↑ 64.0%
Net Income	$-66.8M	↓ 21.86%
Net Profit Margin	-136.06%	↑ 149.53%

	FY22	Y/Y Change
Revenue	$41.6M	↓ 15.32%
Net Income	$-131.2M	↑ 96.35%
Net Profit Margin	-315.48%	↓ 179.42%

	FY23	Y/Y Change
Revenue	$43.9M	↑ 5.68%
Net Income	$-154.9M	↑ 18.1%
Net Profit Margin	-352.56%	↓ 37.08%

	FY24	Y/Y Change
Revenue	$36.1M	↓ 17.78%
Net Income	$-215.3M	↑ 38.97%
Net Profit Margin	-595.93%	↓ 243.37%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$7.9M	↓ 11.75%
Net Income	$-34.5M	↓ 42.72%
Net Profit Margin	-436.76%	↑ 236.17%

	Q2 FY24	Q/Q Change
Revenue	$7.3M	↓ 7.06%
Net Income	$-50.0M	↑ 45.23%
Net Profit Margin	-682.52%	↓ 245.76%

	Q3 FY24	Q/Q Change
Revenue	$11.8M	↑ 60.56%
Net Income	$-99.9M	↑ 99.64%
Net Profit Margin	-848.67%	↓ 166.15%

	Q4 FY24	Q/Q Change
Revenue	$9.1M	↓ 22.36%
Net Income	$-30.9M	↓ 69.05%
Net Profit Margin	-338.33%	↑ 510.34%

	Q1 FY25	Q/Q Change
Revenue	$26.5M	↑ 189.8%
Net Income	$-96.5M	↑ 211.98%
Net Profit Margin	-364.22%	↓ 25.89%

	Q2 FY25	Q/Q Change
Revenue	$8.8M	↓ 66.67%
Net Income	$-158.2M	↑ 64.0%
Net Profit Margin	-1.8K%	↓ 1428.01%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-18.5M	↓ 151.77%

	FY20	Y/Y Change
Profit	$-27.4M	↑ 48.02%

	FY21	Y/Y Change
Profit	$-37.2M	↑ 35.66%

	FY22	Y/Y Change
Profit	$29.6M	↓ 179.67%

	FY23	Y/Y Change
Profit	$43.9M	↑ 48.45%

	FY24	Y/Y Change
Profit	$36.1M	↓ 17.78%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$7.3M	↓ 126.09%

	Q2 FY24	Q/Q Change
Profit	$7.3M	↑ 0.69%

	Q3 FY24	Q/Q Change
Profit	$11.8M	↑ 60.56%

	Q4 FY24	Q/Q Change
Profit	$9.1M	↓ 22.36%

	Q1 FY25	Q/Q Change
Profit	$26.5M	↑ 189.8%

	Q2 FY25	Q/Q Change
Profit	$8.8M	↓ 66.67%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-63.0M	↑ 36.09%
Investing Cash Flow	$24.2M	↓ 208.83%
Financing Cash Flow	$74.2M	↑ 25.79%

	FY20	Y/Y Change
Operating Cash Flow	$-79.9M	↑ 26.73%
Investing Cash Flow	$-1.5M	↓ 106.15%
Financing Cash Flow	$39.5M	↓ 46.76%

	FY21	Y/Y Change
Operating Cash Flow	$-59.6M	↓ 25.37%
Investing Cash Flow	$-146.6M	↑ 9766.96%
Financing Cash Flow	$282.0M	↑ 613.45%

	FY22	Y/Y Change
Operating Cash Flow	$-149.9M	↑ 151.39%
Investing Cash Flow	$2.8M	↓ 101.91%
Financing Cash Flow	$58.7M	↓ 79.17%

	FY23	Y/Y Change
Operating Cash Flow	$-142.2M	↓ 5.13%
Investing Cash Flow	$-27.0M	↓ 1064.31%
Financing Cash Flow	$230.1M	↑ 291.71%

	FY24	Y/Y Change
Operating Cash Flow	$-185.8M	↑ 30.68%
Investing Cash Flow	$-220.2M	↑ 715.03%
Financing Cash Flow	$494.0M	↑ 114.71%

Q1 FY24

Q2 FY24

Q3 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-44.4M	↑ 27.23%
Investing Cash Flow	$-12.1M	↑ 568.4%
Financing Cash Flow	$30.2M	↓ 2513.06%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$5.8M	↓ 113.04%
Investing Cash Flow	$3.3M	↓ 127.05%
Financing Cash Flow	$443.0M	↑ 1369.02%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-80.4M	↓ 1489.48%
Investing Cash Flow	$-133.7M	↓ 4192.21%
Financing Cash Flow	$10.9M	↓ 97.54%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-96.5M	↑ 44.71%
Investing Cash Flow	$-8.7M	-
Financing Cash Flow	$6.7M	↓ 16.41%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-69.2M	↓ 28.23%
Investing Cash Flow	$-7.5M	↓ 14.4%
Financing Cash Flow	$333.3M	↑ 4842.62%

Merus Nv Technicals Summary

Sell

Neutral

Buy

Merus Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Merus Nv Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Merus Nv	-0.05%	40.43%	31.0%	192.09%	447.89%
Regeneron Pharmaceuticals, Inc.	3.77%	-17.64%	-51.18%	-2.19%	-7.17%
Beone Medicines Ltd	-0.02%	10.33%	51.07%	81.16%	24.14%
Vertex Pharmaceuticals Incorporated	-16.39%	-18.24%	-20.49%	39.42%	40.54%
Alnylam Pharmaceuticals, Inc.	33.05%	83.22%	57.52%	115.32%	240.85%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Merus Nv	NA	NA	0.0	-5.79	-0.49	-0.23	NA	11.14
Regeneron Pharmaceuticals, Inc.	14.79	14.79	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.69	27.69	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Merus Nv	Buy	$5.1B	447.89%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$62.2B	-7.17%	14.79	31.37%
Beone Medicines Ltd	NA	$36.8B	24.14%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$99.8B	40.54%	27.69	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.1B	240.85%	NA	-12.96%

Merus Nv Dividend announcements

Merus Nv Earnings
Merus Nv’s price-to-earnings ratio stands at None

About Merus Nv

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Organization	Merus Nv
Employees	260
CEO	Dr. Sven Ante Lundberg M.D.
Industry	Health Technology

Key Management of Merus Nv

Name	Title
Dr. Sven Ante Lundberg M.D.	CEO, President & Executive Director
Mr. Gregory D. Perry	Chief Financial Officer
Mr. Peter B. Silverman J.D.	EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal
Dr. Fabian Zohren M.D., Ph.D.	Chief Medical Officer
Dr. Hennie Hoogenboom	Co-Founder and Scientific Advisor
Mr. Harry Shuman	Chief Accounting Officer
Mr. Cornelis Adriaan de Kruif Ph.D.	CTO & Executive VP
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.	Chief Scientific Officer & Senior VP
Ms. Kathleen Farren	IR & Corporate Communications Officer
Ms. Audrey Bergan	Chief People Officer

Important FAQs about investing in MRUS Stock from India :

What is Merus Nv share price today?

Merus Nv share price today is $66.12 as on August 29, 2025 at 1:29 am IST at the close of the market. Merus Nv share today touched a day high of $69.08 and a low of $66.11.

What is the 52 week high and 52 week low for Merus Nv share?

Merus Nv share touched a 52 week high of $69.08 and a 52 week low of $33.19. Merus Nv stock price today i.e. August 29, 2025 at 1:29 am IST is closed at $66.12, lower by 4.28% versus the 52 week high.

How to invest in Merus Nv Stock (MRUS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Merus Nv on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Merus Nv Shares that will get you 0.0227 shares as per Merus Nv share price of $66.12 per share as on August 29, 2025 at 1:29 am IST.

What is the minimum amount required to buy Merus Nv Stock (MRUS) from India?

Indian investors can start investing in Merus Nv (MRUS) shares with as little as ₹87.6463 or $1 (as of August 29, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹876.46 in Merus Nv stock (as per the Rupee-Dollar exchange rate as on August 29, 2025). Based on Merus Nv share’s latest price of $66.12 as on August 29, 2025 at 1:29 am IST, you will get 0.1512 shares of Merus Nv. Learn more about fractional shares .

What are the returns that Merus Nv has given to Indian investors in the last 5 years?

Merus Nv stock has given 447.89% share price returns and 19.64% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?